Declan Murphy on Theranostics and Future of PSMA PET/CT for Prostate Cancer

Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.

From the 2020 SUO Meeting, Professor Declan Murphy, of the Peter MacCallum Cancer Centre, spoke with CancerNetwork about the future of PSMA PET/CT imaging and the looming advancements with PSMA theranostics.


But finally, the really, really big area looming on the horizon is PSMA theranostics. So, because we know the PSMA molecule is overexpressed on aggressive prostate cancer, especially for example metastatic castration-resistant prostate cancer, we can actually target that using theranostic agents. So, when the PET scan shows lots of this avidity and so on, we can then label a PSMA molecule with a therapy molecule like for example lutetium-177, a beta-emitter. Effectively you can inject this combined ligand with the PSMA ligand and the lutetium, and the lutetium will be brought to the sites of disease.

So, I think this area will be one in which we will have many, many opportunities to see how we can improve outcomes for patients because these therapy projects will be easier to measure in terms of oncologic outcomes compared to the diagnostic opportunities we already have with PSMA PET/CT. So, I think it’s a very exciting decade or more ahead for those interested in PSMA and prostate cancer.

Related Videos
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Related Content